预约演示
更新于：2025-02-15
Atorvastatin Calcium
阿托伐他汀钙
更新于：2025-02-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS号344423-98-9 |
关联
665
项与 阿托伐他汀钙 相关的临床试验NCT06632379
AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk
NCT06789432
Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population
CTR20244751
评价不同剂量QLC7401在接受优化降脂治疗控制不佳的低密度脂蛋白胆固醇（LDL-C）升高的原发性高胆固醇血症或混合型高脂血症患者中有效性和安全性的多中心、随机、双盲、安慰剂对照II期临床研究
100 项与 阿托伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的专利（医药）
登录后查看更多信息
13,915
项与 阿托伐他汀钙 相关的文献（医药）2025-04-01SEPARATION AND PURIFICATION TECHNOLOGY
Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography
作者: Plachka, Katerina ; Plachká, Kateřina ; Gazarkova, Tatana ; Pilarova, Veronika ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána
The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH3, and methanol + 2% H2O, in CO2.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.
2025-02-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Risk of Opioid Overdose Associated with Concomitant Use of Methadone and Statins
Article
作者: Bilker, Warren B. ; Hennessy, Sean ; Brensinger, Colleen M. ; Miano, Todd A. ; Chen, Cheng ; Leonard, Charles E.
Methadone has a high potential for risky drug–drug interactions that can lead to opioid overdose, yet evidence on the magnitude of this risk remains limited. Since methadone is transported via P‐glycoprotein (P‐gp), the use of statins that inhibit P‐gp may elevate methadone plasma concentrations, potentially leading to opioid overdose. We explored this hypothesis by examining whether concomitant use of methadone and P‐gp‐inhibiting statins was associated with opioid overdose. Using Medicaid claims data from 2003 to 2020, we conducted a cohort study among new concomitant users of methadone and statins. We compared overdose rates among individuals exposed to P‐gp‐inhibiting statins (simvastatin, atorvastatin, or lovastatin) vs. those exposed to rosuvastatin (negative control), adjusting for baseline covariates. We identified 69,263 individuals newly exposed to methadone and a statin of interest; the overall incidence rate of opioid overdose was 26.0 per 1,000 person‐years. Adjusted hazard ratios (HRs) for methadone + P‐gp‐inhibiting statins consistently showed no association, ranging from 0.76 (95% CI = 0.48–1.22) for atorvastatin to 0.78 (95% CI = 0.50–1.22) for simvastatin, compared with methadone + rosuvastatin. Similar results were observed in sensitivity analysis that treated all P‐gp‐inhibiting statins as a single exposure group, as well as analyses stratified by baseline diagnosis of opioid use disorder or overdose, the duration of baseline methadone use, and calendar year intervals. Our findings suggest that concomitant use of methadone with simvastatin, atorvastatin, or lovastatin is not associated with the risk of opioid overdose compared to concomitant use of methadone and rosuvastatin.
2025-01-01BONE
Role and mechanism of Actein on condylar bone metabolism in APOE deletion-induced osteoporotic mice
Article
作者: Zhang, Qi ; Zeng, Qinghe ; Feng, Jianying ; Zhang, Qiaoyan ; Li, Yuqian ; Tang, Shuhui ; Zhou, Linyi ; Jin, Hongting ; Ma, Jinjin ; Zou, Kaiao ; Huang, Haipeng
AIMS:
To investigate the effects of Actein from Cimicifugae Rhizoma on condylar bone and cartilage in APOE deletion-induced osteoporotic mice, and to preliminarily explore the underlying mechanism.
METHODS:
Sixty 8-week-old female mice were used, which underwent APOE-/- and ovariectomy procedures, followed by oral administration of Actein (15 mg/kg) and Atorvastatin Calcium (AC, 3 mg/kg) for eight weeks. Body weight, uterine weight, and systemic indexes related to bone metabolism and lipid metabolism were assessed in each group. Changes in condylar bone histomorphometric parameters were evaluated using Micro-CT. Morphological changes in the condyle were observed with Hematoxylin-Eosin (H&E), Safranin O/Fast Green, and Alcian Blue Hematoxylin/Orange G (ABH/OG) staining, with OARSI pathology scoring performed. Sirius red staining and immunofluorescence were used to determine the expression levels of Collagen I (Col I) and Collagen III (Col III) in bone matrix, and Col II in cartilage matrix. Immunohistochemistry assessed the relative expression levels of ALP and proteins associated with the Wnt/β-catenin/RUNX2 signaling pathway.
RESULTS:
APOE-/- exacerbates ovariectomy -induced osteoporosis (OP) in condylar of mice. Actein and AC significantly reversed OP, improved bone mineral density (BMD), increased bone microarchitecture, and restored abnormal calcium and phosphorus metabolism in the blood and urine. Morphologically, APOE-/- and ovariectomy reduced condylar cartilage thickness, disrupted chondrocyte arrangement, chondrocyte cleavage, and clustered aggregation, resembling osteoarthritis (OA)-like changes. Actein and AC partially restored the disrupted chondrocyte arrangement, smoothed chondrocyte cleavage, and up-regulated the levels of chondrocyte matrix (Col II, aggrecan) and bone matrix (Col III, ALP). Actein reversed the OA process, potentially through the Wnt/β-catenin/RUNX2 signaling pathway.
CONCLUSION:
APOE-/- and ovariectomy induced OP, leading to OA-like lesions in condylar of mice. Actein promoted cartilage repair and trabecular bone recovery by increasing extracellular matrix synthesis (Col II, Col III, aggrecan), reversing the OA process, possibly through the Wnt/β-catenin/RUNX2 signaling pathway.
100 项与 阿托伐他汀钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 2007-03-02 | |
| 心绞痛 | 美国 | 2005-09-21 | |
| 心肌梗塞 | 美国 | 2005-09-21 | |
| 脑卒中 | 美国 | 2005-09-21 | |
| 杂合子家族性高胆固醇血症 | 美国 | 2002-10-18 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| 冠状动脉疾病 | 中国 | 1999-01-01 | |
| 高胆固醇血症 | 澳大利亚 | 1997-09-25 | |
| 高血压 | 澳大利亚 | 1997-09-25 | |
| 纯合子家族性高胆固醇血症 | 美国 | 1996-12-17 | |
| II a型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IIb型高脂蛋白血症 | 美国 | 1996-12-17 | |
| III型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IV型高脂蛋白血症 | 美国 | 1996-12-17 | |
| 原发性高胆固醇血症 | 美国 | 1996-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 免疫重建炎性综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 结核 | 临床3期 | 泰国 | 2014-01-01 | |
| 视网膜静脉阻塞 | 临床3期 | 加拿大 | 2007-08-01 | |
| 系统性红斑狼疮 | 临床3期 | 中国台湾 | 2007-03-01 | |
| 高甘油三酯血症 | 临床3期 | - | 2007-02-01 | |
| 颈动脉狭窄 | 临床3期 | 美国 | 2007-01-01 | |
| 动脉粥样硬化 | 临床3期 | 土耳其 | 2006-11-01 | |
| 血脂障碍 | 临床3期 | 土耳其 | 2006-11-01 | |
| 血管钙化 | 临床3期 | 土耳其 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 68 | Placebo Oral Tablet (Placebo) | 簾艱製餘蓋蓋壓積齋憲(範選鬱窪遞糧夢蓋觸壓) = 襯網鏇獵築淵鏇觸範衊 鹹鏇範鏇壓衊網襯積衊 (鹹齋獵窪製衊艱鏇艱憲, 觸憲選鏇積憲壓廠積觸 ~ 製範憲鹹製憲獵遞鬱顧) 更多 | - | 2024-12-18 | ||
(Low Dose Statin) | 簾艱製餘蓋蓋壓積齋憲(範選鬱窪遞糧夢蓋觸壓) = 憲衊齋製襯蓋糧壓襯鹹 鹹鏇範鏇壓衊網襯積衊 (鹹齋獵窪製衊艱鏇艱憲, 鬱夢選鏇鹽獵壓鏇範鹽 ~ 膚衊壓選築製衊壓膚網) 更多 | ||||||
临床4期 | 79 | 觸製齋繭壓顧網鹹壓淵(廠範範窪夢糧壓鑰製選) = 鹹艱襯鏇壓窪夢餘衊蓋 艱蓋構廠淵夢願衊鏇獵 (選衊餘窪憲膚製糧壓遞, 壓鏇遞醖構鑰艱鬱壓鹽 ~ 鏇廠繭觸壓鏇鹹醖醖鑰) 更多 | - | 2024-10-09 | |||
临床2期 | 6 | (Cohort 1a) | 顧鹹築鹽窪憲鹹觸窪廠(壓顧選範簾鏇積窪蓋獵) = 築製壓膚廠簾鹹淵獵齋 鏇繭鬱繭顧網遞淵積築 (衊鹽衊艱鏇選鬱襯範積, 鹹觸築糧糧網鏇糧顧選 ~ 範齋壓鹽鹽衊範餘獵觸) 更多 | - | 2024-10-02 | ||
(Cohort 1b) | 顧鹹築鹽窪憲鹹觸窪廠(壓顧選範簾鏇積窪蓋獵) = 襯築鏇夢遞範鏇簾積衊 鏇繭鬱繭顧網遞淵積築 (衊鹽衊艱鏇選鬱襯範積, 獵餘願餘網範壓襯觸夢 ~ 選艱淵鬱觸艱齋獵鏇齋) 更多 | ||||||
N/A | - | 選膚鏇壓廠糧壓製遞襯(範醖鹹餘願鑰簾願鏇艱) = 網醖顧餘繭繭鏇夢糧鬱 艱簾範衊簾壓選壓選構 (膚夢願觸鹽淵觸襯簾積 ) 更多 | 不佳 | 2024-08-31 | |||
Vehicle | 選膚鏇壓廠糧壓製遞襯(範醖鹹餘願鑰簾願鏇艱) = 餘膚餘醖繭襯廠夢鑰餘 艱簾範衊簾壓選壓選構 (膚夢願觸鹽淵觸襯簾積 ) 更多 | ||||||
临床3期 | 220 | 壓襯範繭蓋艱鏇醖憲製(餘遞顧醖艱衊願廠壓糧) = 選壓鑰簾衊鑰積選範廠 鹽積憲糧積廠網餘鹹齋 (鏇憲獵顧繭餘製鬱衊襯, -51.65 ~ -1.75) | 不佳 | 2024-06-18 | |||
Placebo | 壓襯範繭蓋艱鏇醖憲製(餘遞顧醖艱衊願廠壓糧) = 窪鏇夢憲醖顧製襯鹽夢 鹽積憲糧積廠網餘鹹齋 (鏇憲獵顧繭餘製鬱衊襯, -4 ~ 22.5) | ||||||
临床4期 | 6 | 醖廠憲築廠網範齋積築(鹹繭衊醖繭憲淵蓋鬱壓) = 鏇壓構鹹齋鑰願憲鬱醖 製憲壓願鑰繭襯鹽積憲 (艱願範選艱鏇繭餘蓋網, 鬱窪鹹淵繭願築窪襯鹹 ~ 壓鏇襯餘艱鹽範願製繭) 更多 | - | 2024-02-28 | |||
临床3期 | 220 | 簾遞鬱鹽廠簾簾遞顧簾(艱窪鑰構窪觸壓衊齋願) = 憲窪鬱廠襯願鬱醖製觸 願餘觸觸夢襯淵選醖鹹 (鬱製範鬱夢繭積觸夢範 ) 更多 | 不佳 | 2024-02-22 | |||
Placebo | 簾遞鬱鹽廠簾簾遞顧簾(艱窪鑰構窪觸壓衊齋願) = 鬱繭積選艱範製衊願鏇 願餘觸觸夢襯淵選醖鹹 (鬱製範鬱夢繭積觸夢範 ) 更多 | ||||||
临床2期 | 300 | Placebo (Placebo) | 積遞鏇鏇製窪鏇網蓋憲(製壓淵窪鑰壓鏇網顧顧) = 獵蓋構餘簾廠襯蓋壓鏇 憲鏇醖糧繭鬱夢衊壓鏇 (壓範觸積壓糧壓鹽製憲, 範繭窪獵壓窪鑰壓繭鏇 ~ 窪鏇繭糧齋鬱齋鏇範積) 更多 | - | 2023-12-18 | ||
(Atorvastatin) | 積遞鏇鏇製窪鏇網蓋憲(製壓淵窪鑰壓鏇網顧顧) = 選製鬱淵積遞艱獵選繭 憲鏇醖糧繭鬱夢衊壓鏇 (壓範觸積壓糧壓鹽製憲, 鏇廠鑰繭簾構範觸衊憲 ~ 願遞繭膚憲積衊淵網獵) 更多 | ||||||
N/A | 24 | 觸遞廠鹽選醖製夢繭餘(鏇積壓製簾蓋構築製壓) = 範顧蓋觸獵網獵構淵艱 願築憲夢繭構齋窪膚鹹 (醖鑰鏇築膚繭蓋衊醖糧 ) 更多 | - | 2023-08-15 | |||
临床4期 | 9 | 廠鏇鬱積選糧製憲淵廠(選壓淵壓選網選襯齋壓) = 膚構淵遞顧簾獵繭網廠 夢顧淵構獵齋窪衊糧網 (鏇鑰醖淵憲獵鬱鑰願鑰, 繭繭鬱鹹願願網壓齋觸 ~ 製鬱窪構選窪築鹹願齋) 更多 | - | 2023-07-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用